Bank of New York Mellon Corp Has $1.32 Billion Stock Holdings in Bristol Myers Squibb Company $BMY

Bank of New York Mellon Corp lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 47.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 24,495,875 shares of the biopharmaceutical company’s stock after buying an additional 7,837,485 shares during the quarter. Bank of New York Mellon Corp’s holdings in Bristol Myers Squibb were worth $1,321,308,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. waypoint wealth counsel acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $1,194,000. Life Cycle Investment Partners Ltd acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $34,406,000. Axxcess Wealth Management LLC boosted its position in Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after acquiring an additional 21,196 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in Bristol Myers Squibb by 6.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock worth $23,972,000 after acquiring an additional 32,005 shares during the last quarter. Finally, M&G PLC boosted its position in Bristol Myers Squibb by 1.4% during the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after acquiring an additional 97,063 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb won expanded EU approval for Opdivo in combination with AVD as a frontline treatment for newly diagnosed advanced classical Hodgkin lymphoma, which could broaden use of one of its key cancer drugs. BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
• Positive Sentiment: The FDA accepted Camzyos for priority review in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, signaling a potential label expansion that could open a new patient population for the drug. FDA Accepts Camzyos Supplemental New Drug Application
• Positive Sentiment: Recent ASCO data highlighted progress in BMY’s late-stage pipeline, including mezigdomide and pumitamig, reinforcing the company’s growth story beyond legacy products. Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
• Neutral Sentiment: Unusual options activity showed traders buying a large number of call options, which can reflect speculation that more positive news could continue, but it does not by itself confirm a fundamental change.
• Negative Sentiment: Some commentary remains cautious, noting that BMY still faces patent-expiration headwinds through 2028 and that its stock may not be as cheap as it appears on traditional valuation measures. Why Bristol Myers Squibb Stock Isn’t Nearly As Cheap As It Looks

Bristol Myers Squibb Trading Down 1.1%

Shares of Bristol Myers Squibb stock opened at $54.34 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The stock has a market cap of $110.97 billion, a P/E ratio of 15.26, a P/E/G ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business’s 50 day moving average is $58.25 and its 200-day moving average is $56.37.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business posted $1.80 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BMY. Barclays began coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Morgan Stanley reiterated an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Cantor Fitzgerald upped their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.